688658 悦康药业
已收盘 11-06 15:00:00
资讯
新帖
简况
股市必读：悦康药业新发布《2026年第二次临时股东会会议资料》
证券之星 · 11-05 01:54
股市必读：悦康药业新发布《2026年第二次临时股东会会议资料》
悦康药业(688658)9月30日股东户数1.72万户，较上期增加10.74%
证券之星 · 10-29
悦康药业(688658)9月30日股东户数1.72万户，较上期增加10.74%
悦康药业：关于召开2026年第二次临时股东会的通知
同花顺 · 10-28
悦康药业：关于召开2026年第二次临时股东会的通知
悦康药业：公司无逾期担保
同花顺 · 10-28
悦康药业：公司无逾期担保
悦康药业：关于部分募投项目变更并将剩余募集资金及剩余超募资金投入新募投项目的公告
同花顺 · 10-28
悦康药业：关于部分募投项目变更并将剩余募集资金及剩余超募资金投入新募投项目的公告
股市必读：悦康药业新发布《关于自愿披露新药紫花温肺止嗽颗粒获得上市批准的公告》
证券之星 · 10-19
股市必读：悦康药业新发布《关于自愿披露新药紫花温肺止嗽颗粒获得上市批准的公告》
悦康药业(688658.SH)：新药紫花温肺止嗽颗粒获得上市批准
智通财经 · 10-15
悦康药业(688658.SH)：新药紫花温肺止嗽颗粒获得上市批准
悦康药业最新公告：子公司YKYY036注射液获中美临床试验批准
证券之星 · 10-13
悦康药业最新公告：子公司YKYY036注射液获中美临床试验批准
悦康药业（688658）10月8日主力资金净卖出1478.27万元
证券之星 · 10-09
悦康药业（688658）10月8日主力资金净卖出1478.27万元
8月31日悦康药业跌6.10%，鹏华量化先锋混合基金重仓该股
证券之星 · 08-31
8月31日悦康药业跌6.10%，鹏华量化先锋混合基金重仓该股
8月28日悦康药业跌6.73%，鹏华量化先锋混合基金重仓该股
证券之星 · 08-28
8月28日悦康药业跌6.73%，鹏华量化先锋混合基金重仓该股
8月26日悦康药业涨6.67%，鹏华量化先锋混合基金重仓该股
证券之星 · 08-26
8月26日悦康药业涨6.67%，鹏华量化先锋混合基金重仓该股
悦康药业涨6.67%，开源证券一日前给出“买入”评级
证券之星 · 08-26
悦康药业涨6.67%，开源证券一日前给出“买入”评级
开源证券：给予悦康药业买入评级
证券之星 · 08-25
开源证券：给予悦康药业买入评级
8月24日悦康药业跌7.69%，鹏华量化先锋混合基金重仓该股
证券之星 · 08-24
8月24日悦康药业跌7.69%，鹏华量化先锋混合基金重仓该股
股市必读：悦康药业中报 - 第二季度单季净利润同比下降44.87%
证券之星 · 08-24
股市必读：悦康药业中报 - 第二季度单季净利润同比下降44.87%
悦康药业（688658）2026年中报简析：增收不增利
证券之星 · 08-22
悦康药业（688658）2026年中报简析：增收不增利
悦康药业(688658)6月30日股东户数1.56万户，较上期增加5.41%
证券之星 · 08-21
悦康药业(688658)6月30日股东户数1.56万户，较上期增加5.41%
图解悦康药业中报：第二季度单季净利润同比下降44.87%
证券之星 · 08-21
图解悦康药业中报：第二季度单季净利润同比下降44.87%
8月20日悦康药业涨19.98%，鹏华量化先锋混合基金重仓该股
证券之星 · 08-20
8月20日悦康药业涨19.98%，鹏华量化先锋混合基金重仓该股
加载更多
公司概况
公司名称：
悦康药业集团股份有限公司
所属行业：
医药制造业
上市日期：
2020-12-24
主营业务：
悦康药业集团股份有限公司的主营业务是药品研发、生产制造、流通销售。公司的主要产品是心脑血管疾病药品、抗肿瘤药品、抗病毒药品、糖尿病药品、消化系统药品、生殖健康药品。公司多次荣获工信部医药工业百强和中国医药研发产品线最佳工业企业的殊荣。
发行价格：
24.36
{"stockData":{"symbol":"688658","market":"SH","secType":"STK","nameCN":"悦康药业","latestPrice":11.5,"timestamp":1793948400000,"preClose":11.64,"halted":0,"volume":10938800,"delay":0,"changeRate":-0.012,"floatShares":450000000,"shares":450000000,"eps":-0.7072,"marketStatus":"已收盘","change":-0.14,"latestTime":"11-06 15:00:00","open":11.12,"high":11.75,"low":11.1,"amount":126000000,"amplitude":0.0558,"askPrice":11.51,"askSize":39,"bidPrice":11.5,"bidSize":96,"shortable":0,"etf":0,"ttmEps":-0.7072,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794187800000},"marketStatusCode":5,"adr":0,"adjPreClose":11.64,"symbolType":"stock_kcb","openAndCloseTimeList":[[1793928600000,1793935800000],[1793941200000,1793948400000]],"highLimit":12.8,"lowLimit":10.48,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":450000000,"isCdr":false,"pbRate":1.66,"roa":"--","roe":"--","epsLYR":-0.59,"committee":0.806207,"marketValue":5175000000,"turnoverRate":0.0243,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-11-09。","afterMarket":{"amount":0,"volume":0,"close":11.5,"buyVolume":0,"sellVolume":0,"time":1793950437746,"indexStatus":"已收盘 11-06 15:30:00","preClose":11.64},"floatMarketCap":5175000000},"requestUrl":"/m/hq/s/688658","defaultTab":"news","newsList":[{"id":"2681189069","title":"股市必读：悦康药业新发布《2026年第二次临时股东会会议资料》","url":"https://stock-news.laohu8.com/highlight/detail?id=2681189069","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681189069?lang=zh_cn&edition=full","pubTime":"2026-11-05 01:54","pubTimestamp":1793814882,"startTime":"0","endTime":"0","summary":"截至2026年11月4日收盘，悦康药业报收于11.22元，上涨4.47%，换手率2.33%，成交量10.5万手，成交额1.16亿元。公司公告汇总2026年第二次临时股东会会议资料悦康药业集团股份有限公司拟变更部分募集资金用途，将原“营销中心建设项目”剩余募集资金4,013.32万元及剩余超募资金115.39万元，合计4,128.71万元，用于投资新项目“RSV及乙肝创新药研发项目”。新项目总投资4,200.00万元，实施主体为公司及下属子公司，主要用于YKYY018和YKYY013两个创新药的II期临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110500003568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679084014","title":"悦康药业(688658)9月30日股东户数1.72万户，较上期增加10.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679084014","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679084014?lang=zh_cn&edition=full","pubTime":"2026-10-29 18:58","pubTimestamp":1793271532,"startTime":"0","endTime":"0","summary":"证券之星消息，近日悦康药业披露，截至2026年9月30日公司股东户数为1.72万户，较6月30日增加1672.0户，增幅为10.74%。在化学制药行业个股中，悦康药业股东户数低于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.95万户。从股价来看，2026年6月30日至2026年9月30日，悦康药业区间涨幅为9.18%，在此期间股东户数增加1672.0户，增幅为10.74%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900045238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678549639","title":"悦康药业：关于召开2026年第二次临时股东会的通知","url":"https://stock-news.laohu8.com/highlight/detail?id=2678549639","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678549639?lang=zh_cn&edition=full","pubTime":"2026-10-28 21:32","pubTimestamp":1793194320,"startTime":"0","endTime":"0","summary":" 证券日报网讯 10月28日，悦康药业发布公告称，公司将于2026年11月13日召开2026年第二次临时股东会。 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261028/c681207909.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261028/c681207909.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678464329","title":"悦康药业：公司无逾期担保","url":"https://stock-news.laohu8.com/highlight/detail?id=2678464329","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678464329?lang=zh_cn&edition=full","pubTime":"2026-10-28 19:23","pubTimestamp":1793186580,"startTime":"0","endTime":"0","summary":" 证券日报网讯 10月28日，悦康药业发布公告称，截至本公告披露日，公司对外担保总额(担保总额是指已批准的额度范围内尚未使用的额度与担保实际发生余额之和)为 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261028/c681202972.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261028/c681202972.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678464321","title":"悦康药业：关于部分募投项目变更并将剩余募集资金及剩余超募资金投入新募投项目的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2678464321","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678464321?lang=zh_cn&edition=full","pubTime":"2026-10-28 19:23","pubTimestamp":1793186580,"startTime":"0","endTime":"0","summary":" 证券日报网讯 10月28日，悦康药业发布公告称，公司于2026年10月28日召开第三届董事会审计委员会2026年第五次会议、第三届董事会第八次会议，审议通过《关于变 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261028/c681202962.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261028/c681202962.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676140573","title":"股市必读：悦康药业新发布《关于自愿披露新药紫花温肺止嗽颗粒获得上市批准的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2676140573","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676140573?lang=zh_cn&edition=full","pubTime":"2026-10-19 03:38","pubTimestamp":1792352290,"startTime":"0","endTime":"0","summary":"交易信息汇总资金流向10月16日主力资金净流出155.25万元，占总成交额0.64%；游资资金净流出406.15万元，占总成交额1.66%；散户资金净流入561.4万元，占总成交额2.3%。公司公告汇总关于自愿披露新药紫花温肺止嗽颗粒获得上市批准的公告悦康药业集团股份有限公司子公司广州悦康生物制药有限公司收到国家药品监督管理局核准签发的《药品注册证书》，紫花温肺止嗽颗粒获得上市批准。上市许可持有人和生产企业均为广州悦康生物制药有限公司。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900001107.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675358928","title":"悦康药业(688658.SH)：新药紫花温肺止嗽颗粒获得上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2675358928","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675358928?lang=zh_cn&edition=full","pubTime":"2026-10-15 19:19","pubTimestamp":1792063161,"startTime":"0","endTime":"0","summary":"智通财经APP讯，悦康药业(688658.SH)发布公告，近日，公司子公司广州悦康生物制药有限公司收到国家药品监督管理局核准签发的《药品注册证书》，公司新药紫花温肺止嗽颗粒获得了上市批准。紫花温肺止嗽颗粒为中药1.1类，该药品处方源自临床经验方，具有温肺止咳的功效，用于风寒恋肺证的咳嗽。该药品的上市为病程3‑6周的风寒恋肺证咳嗽患者提供了新的用药选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1507874.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675355928","title":"悦康药业最新公告：子公司YKYY036注射液获中美临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2675355928","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675355928?lang=zh_cn&edition=full","pubTime":"2026-10-13 18:51","pubTimestamp":1791888674,"startTime":"0","endTime":"0","summary":"悦康药业(688658.SH)公告称，公司子公司北京悦康科创和杭州天龙药业近日获国家药监局批准，同意YKYY036注射液用于肥胖或超重适应症的临床试验。同时，北京悦康科创收到美国FDA关于同意该注射液开展临床试验的函告。YKYY036注射液为自主研发的靶向INHBE基因的siRNA药物，临床前研究显示其具有显著药理活性和良好安全性。本次获批是公司新药研发的阶段性成果，对近期业绩不会产生重大影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300032997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674889936","title":"悦康药业（688658）10月8日主力资金净卖出1478.27万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674889936","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674889936?lang=zh_cn&edition=full","pubTime":"2026-10-09 08:31","pubTimestamp":1791505886,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月8日收盘，悦康药业报收于13.18元，下跌6.13%，换手率4.12%，成交量18.55万手，成交额2.51亿元。近5日资金流向一览见下表：悦康药业融资融券信息显示，融资方面，当日融资买入2166.88万元，融资偿还1651.13万元，融资净买入515.75万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900006194.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663507592","title":"8月31日悦康药业跌6.10%，鹏华量化先锋混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2663507592","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663507592?lang=zh_cn&edition=full","pubTime":"2026-08-31 16:39","pubTimestamp":1788165590,"startTime":"0","endTime":"0","summary":"证券之星消息，8月31日悦康药业跌6.10%，收盘报13.4元，换手率4.73%，成交量21.28万手，成交额2.88亿元。重仓悦康药业的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为鹏华基金的鹏华量化先锋混合。鹏华量化先锋混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100022328.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662068372","title":"8月28日悦康药业跌6.73%，鹏华量化先锋混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2662068372","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662068372?lang=zh_cn&edition=full","pubTime":"2026-08-28 16:36","pubTimestamp":1787906188,"startTime":"0","endTime":"0","summary":"证券之星消息，8月28日悦康药业跌6.73%，收盘报14.27元，换手率5.44%，成交量24.48万手，成交额3.59亿元。重仓悦康药业的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为鹏华基金的鹏华量化先锋混合。鹏华量化先锋混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800038070.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662960707","title":"8月26日悦康药业涨6.67%，鹏华量化先锋混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2662960707","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662960707?lang=zh_cn&edition=full","pubTime":"2026-08-26 16:35","pubTimestamp":1787733304,"startTime":"0","endTime":"0","summary":"证券之星消息，8月26日悦康药业涨6.67%，收盘报14.72元，换手率7.13%，成交量32.09万手，成交额4.59亿元。重仓悦康药业的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为鹏华基金的鹏华量化先锋混合。鹏华量化先锋混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600036654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662796297","title":"悦康药业涨6.67%，开源证券一日前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2662796297","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662796297?lang=zh_cn&edition=full","pubTime":"2026-08-26 16:34","pubTimestamp":1787733295,"startTime":"0","endTime":"0","summary":"今日悦康药业涨6.67%，收盘报14.72元。2026年8月25日，开源证券研究员余汝意,巢舒然发布了对悦康药业的研报《公司信息更新报告：2026H1业绩相对承压，前瞻布局mRNA肿瘤疫苗》，该研报对悦康药业给出“买入”评级。悦康药业个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600036650.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662880785","title":"开源证券：给予悦康药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2662880785","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662880785?lang=zh_cn&edition=full","pubTime":"2026-08-25 12:22","pubTimestamp":1787631721,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意,巢舒然近期对悦康药业进行研究并发布了研究报告《公司信息更新报告：2026H1业绩相对承压，前瞻布局mRNA肿瘤疫苗》，给予悦康药业买入评级。 悦康药业 经营业绩相对承压，创新管线布局丰富，维持“买入”评级 2026H1公司实现营收11.81亿元，归母净利润-1.05亿元；扣非归母净利润-1.13亿元。最新盈利预测明细如下：本文数据来源于开源证券股份有限公司，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500024126.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661217102","title":"8月24日悦康药业跌7.69%，鹏华量化先锋混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2661217102","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661217102?lang=zh_cn&edition=full","pubTime":"2026-08-24 16:35","pubTimestamp":1787560552,"startTime":"0","endTime":"0","summary":"证券之星消息，8月24日悦康药业跌7.69%，收盘报13.21元，换手率8.62%，成交量38.8万手，成交额5.24亿元。重仓悦康药业的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为鹏华基金的鹏华量化先锋混合。鹏华量化先锋混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400021946.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661243244","title":"股市必读：悦康药业中报 - 第二季度单季净利润同比下降44.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661243244","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661243244?lang=zh_cn&edition=full","pubTime":"2026-08-24 01:11","pubTimestamp":1787505069,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，悦康药业报收于14.31元，下跌7.62%，换手率11.57%，成交量52.08万手，成交额7.44亿元。业绩披露要点：2026年第二季度单季度归母净利润为-7179.29万元，同比下降44.87%；扣非净利润为-7517.63万元，同比下降36.7%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400000810.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661218374","title":"悦康药业（688658）2026年中报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2661218374","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661218374?lang=zh_cn&edition=full","pubTime":"2026-08-22 06:07","pubTimestamp":1787350053,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期悦康药业发布2026年中报。根据财报显示，悦康药业增收不增利。截至本报告期末，公司营业总收入11.81亿元，同比上升1.18%，归母净利润-1.05亿元，同比下降6.14%。本次财报公布的各项数据指标表现一般。持有悦康药业最多的基金为鹏华量化先锋混合，目前规模为0.97亿元，最新净值1.7689，较上一交易日上涨0.86%，近一年上涨16.31%。本文数据来源于悦康药业2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082200004881.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661692992","title":"悦康药业(688658)6月30日股东户数1.56万户，较上期增加5.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661692992","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661692992?lang=zh_cn&edition=full","pubTime":"2026-08-21 17:40","pubTimestamp":1787305225,"startTime":"0","endTime":"0","summary":"证券之星消息，近日悦康药业披露，截至2026年6月30日公司股东户数为1.56万户，较3月31日增加799.0户，增幅为5.41%。在化学制药行业个股中，悦康药业股东户数低于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.68万户。从股价来看，2026年3月31日至2026年6月30日，悦康药业区间跌幅为24.93%，在此期间股东户数增加799.0户，增幅为5.41%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100032343.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661964239","title":"图解悦康药业中报：第二季度单季净利润同比下降44.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661964239","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661964239?lang=zh_cn&edition=full","pubTime":"2026-08-21 01:34","pubTimestamp":1787247244,"startTime":"0","endTime":"0","summary":"证券之星消息，悦康药业2026年中报显示，上半年度公司主营收入11.81亿元，同比上升1.18%；归母净利润-1.05亿元，同比下降6.14%；扣非净利润-1.13亿元，同比下降3.74%；其中2026年第二季度，公司单季度主营收入6.25亿元，同比上升5.95%；单季度归母净利润-7179.29万元，同比下降44.87%；单季度扣非净利润-7517.63万元，同比下降36.7%；负债率36.83%，投资收益296.58万元，财务费用719.53万元，毛利率55.75%。财报数据概要请见下图:本文数据来源于悦康药业2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100001266.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660021104","title":"8月20日悦康药业涨19.98%，鹏华量化先锋混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2660021104","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660021104?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:38","pubTimestamp":1787215127,"startTime":"0","endTime":"0","summary":"证券之星消息，8月20日悦康药业涨19.98%，收盘报15.49元，换手率2.95%，成交量13.27万手，成交额2.06亿元。重仓悦康药业的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为鹏华基金的鹏华量化先锋混合。鹏华量化先锋混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000028890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793995464895,"stockEarnings":[{"period":"1week","weight":0.0808},{"period":"1month","weight":-0.1809},{"period":"3month","weight":-0.1301},{"period":"6month","weight":-0.4654},{"period":"1year","weight":-0.4442},{"period":"ytd","weight":-0.4914}],"compareEarnings":[{"period":"1week","weight":0.0139},{"period":"1month","weight":-0.0502},{"period":"3month","weight":-0.0738},{"period":"6month","weight":-0.127},{"period":"1year","weight":-0.0895},{"period":"ytd","weight":-0.0805}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"悦康药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"17235人(较上一季度增加10.74%)","perCapita":"26109股","listingDate":"2020-12-24","address":"北京市大兴区北京经济技术开发区宏达中路6号","registeredCapital":"45000万元","survey":" 悦康药业集团股份有限公司的主营业务是药品研发、生产制造、流通销售。公司的主要产品是心脑血管疾病药品、抗肿瘤药品、抗病毒药品、糖尿病药品、消化系统药品、生殖健康药品。公司多次荣获工信部医药工业百强和中国医药研发产品线最佳工业企业的殊荣。","listedPrice":24.36},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"悦康药业(688658)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供悦康药业(688658)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"悦康药业,688658,悦康药业股票,悦康药业股票老虎,悦康药业股票老虎国际,悦康药业行情,悦康药业股票行情,悦康药业股价,悦康药业股市,悦康药业股票价格,悦康药业股票交易,悦康药业股票购买,悦康药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"悦康药业(688658)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供悦康药业(688658)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}